Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $13.65 on Wednesday. The firm’s 50 day moving average price is $13.74 and its two-hundred day moving average price is $20.90. Janux Therapeutics has a 52-week low of $12.12 and a 52-week high of $35.34. The stock has a market cap of $821.05 million, a PE ratio of -8.13 and a beta of 2.88.

Insider Activity

In other Janux Therapeutics news, CEO David Alan Campbell sold 8,072 shares of Janux Therapeutics stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the transaction, the chief executive officer owned 284,982 shares of the company’s stock, valued at approximately $3,912,802.86. The trade was a 2.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Zachariah Mciver sold 2,714 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $37,263.22. Following the sale, the insider directly owned 23,286 shares of the company’s stock, valued at $319,716.78. This represents a 10.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 22,366 shares of company stock worth $371,245. Corporate insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. boosted its position in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares during the period. Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Janux Therapeutics during the 4th quarter worth approximately $137,000. Martingale Asset Management L P bought a new position in shares of Janux Therapeutics during the 4th quarter worth approximately $155,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Janux Therapeutics in the fourth quarter valued at approximately $164,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JANX. Cantor Fitzgerald reduced their price target on Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 2nd. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Clear Str cut Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. UBS Group reissued a “buy” rating and set a $57.00 price objective on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Finally, Piper Sandler lowered their target price on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, January 16th. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.08.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.